- Qysmia looks to be gaining from new online marketing efforts
- Endo will start promoting Vivus' ED drug
- 36% short interest!
- Institutional investors adding at these levels
- Recently hit a 10-year-low, but things have never looked brighter for VVUS
Timeframe: 18 - 24 months (possibly sooner, depending on how ED drug sales are)
Disclosure: Long $2...
This chart is a little busy so allow me to explain what whats going on here. The Green trend lines is long term support/resistance formed in the 4th quarter of 2012. The red trend lines were formed in late 2014. And the blue trend lines is the most current trend.
Ultimately, I think we are going to get a prolonged period of sideways volatile action out of...
Above ema 20 at 76.4 on daily... (A nice fib number too) and the stock will move. Might have to see the middle BB giving support before move.
It's a heavily traded handle.
Safe trading ladies & gents!
I have moved on to do many of my publications on my Twitter account due to the easier and much quicker way of making follow up charts. Follow me there...
With the new pressure on Bio's upon us I wanted to take a look at a stock I have long liked and especially like at this level. With new patents and a bunch of new drugs in the pipeline it will happen quickly and suddenly. The chart shows great strength as it has held up when others have fallen and I look for a move over the next month to 4.66. All it needs is a...
After breaking and violating my previous setup on $IBB, the selling action we've seen on expiration date could mean that options traders finally think $IBB has reached too far.
When this selling action comes with a daily bearish AB=CD pattern, it becomes interesting.
If indeed we will see a pullback, the first point of interest will be the meeting point with the...
Sifting through the biotechs I came across this head and shoulders opportunity. Volume pattern confirming so far. We might be close to breakdown. Also notice the RSI trend and latest high right around 51. I suggest a stop above 110, which is about 2x ATR and gives some room. The biotechs as a group are pretty bullish at the moment, so this trade could act as a nice hedge.
I Bought GILD for seven reasons:
(1) Head and Shoulders Pattern (60 min)
(2) Horizontal Support from Left Shoulder ($102.72)
(3) 61.8% Fib level Support @ $102.75
(4) Descending Trend line Support
(5) Long-wicked Hammer found Support at Trend line
(6) Weekly Uptrend
(7) Selling Climax in February 2015
(8) The risk/reward potential is favorable. My reward is based...
Sophiris Bio had a Phase III drug trial test showing the drug was not effective and the market overreacted. The chart has a cash/share value (mrq) of $1.74, the float is 16.78 Million Shares (note today's volume alone is a large part of that), so with a tiny float, more cash per share on hand than the market price, and upcoming results for new Phase III results...
Momentum to the upside has slowed down the past two days. The good news is volume has very light to the downside when compared to the latest volume to the upside. After now hitting the .618 retrace, the correction may be over but we would need to see a pick up in volume and a new high to confirm the continuation of the uptrend. 7.68 is the short term support for now.
Continuing coverage of ACRX this week, we saw ACRX pullback with the market as a whole early this morning. ACRX broke right through support at the .236 retrace, but found support at yesterdays congested zone at the .382 retrace. Uptrend remains in place. $9 remains 1st target. Stop now at 7.70.
After getting hammered in July from the FDA delaying approval on its' latest drug for pain relief, Bears have been piling on making an incredible 20% of the float short. Recent buy ratings from analysts could be the catalyst to get a short squeeze going to begin filling the gap left from the huge 40%+ drop in July. If momentum can carry the stock past 8, then 9...
AS PREVIOUSLY STATED THIS IS ANOTHER BIOTECH THAT WILL CHANGE THE OSTEOARTHRITIS MARKET HOWEVER UNTIL ABOUT AN HOUR AGO THIS WAS SOMETHING THAT COULD NOT BE FOUND AS SIMPLY AS THIS LINK us.rd.yahoo.com . ALL INVESTORS SHOULD POSITION INTO THIS...
This biotech company was sold off aggressively off the highs but caught buying momentum and covered part of those losses. It penetrated a bit higher then the bears wanted. Nevertheless, 8/21 EMA are hit with today's candle as well as trend line. And it triggers Short Entry below $164.00 with STOP above last swing high at $172 makes this trade attractive from R/R...